QuidelOrtho Corporation (QDEL)
NASDAQ: QDEL · Real-Time Price · USD
17.54
-0.70 (-3.84%)
Jul 17, 2026, 2:20 PM EDT - Market open
QuidelOrtho Revenue
QuidelOrtho had revenue of $619.80M in the quarter ending March 29, 2026, a decrease of -10.54%. This brings the company's revenue in the last twelve months to $2.66B, down -3.89% year-over-year. In the year 2025, QuidelOrtho had annual revenue of $2.73B, down -1.89%.
Revenue (ttm)
$2.66B
Revenue Growth
-3.89%
P/S Ratio
0.45
Revenue / Employee
$408,800
Employees
6,500
Market Cap
1.20B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.73B | -52.70M | -1.89% |
| Dec 31, 2024 | 2.78B | -214.90M | -7.17% |
| Dec 31, 2023 | 3.00B | -268.20M | -8.21% |
| Jan 1, 2023 | 3.27B | 1.57B | 92.28% |
| Jan 2, 2022 | 1.70B | 36.90M | 2.22% |
| Jan 3, 2021 | 1.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.29B |
| CONMED | 1.37B |
| Lumexa Imaging Holdings | 1.03B |
| Tandem Diabetes Care | 1.03B |
| Inspire Medical Systems | 915.25M |
| Alphatec Holdings | 787.08M |
| Avanos Medical | 715.90M |
| Bioventus | 576.30M |
QDEL News
- 1 day ago - QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 9 days ago - QuidelOrtho price target raised to $18 from $13 at Citi - TheFly
- 16 days ago - QuidelOrtho price target raised to $12 from $11 at JPMorgan - TheFly
- 18 days ago - QuidelOrtho puts point-of-care testing unit up for sale, FT reports - TheFly
- 18 days ago - QuidelOrtho surges 33% after FT says company looking to sell point-of-care arm - TheFly
- 24 days ago - QuidelOrtho appoints Micah Young as CFO - TheFly
- 24 days ago - QuidelOrtho Appoints Micah Young as Chief Financial Officer - PRNewsWire
- 4 weeks ago - QuidelOrtho Transcript: AGM 2026 - Transcripts